Interferons (IFNs) possess numerous biological activities. In addition to their antiviral activity, interferons are known to have antiproliferative and immunomodulating properties (Gresser et al., 1979) . One of the most thoroughly investigated properties of interferons is their ability to modulate natural killer (NK) cell activity (Einhorn et al., 1978; Skurkovich et al., 1978; Herberman et al., 1979; Maluish et al., 1983) . Augmentation of NK cell activity has been reported in a number of studies. Einhorn et al. (1980) reported an increase in the NK cell activity 12 to 24 h after the first injection of three million units of natural interferon alpha (IFNoc) given daily to 43 patients. In some of these patients, an increase in the NK cell activity was preceded by a reduction. Subsequent treatment maintained an elevated level for up to 9 months. Highly significant and consistant increase in the NK cell activity after a single or multiple injection of three million units of IFN-a2 to patients with low or medium pretreatment levels of NK cell activity were reported by Lotzova et al., (1982) . No change was observed in patients with high pretreatment NK cell activity in these studies. A significant elevation of NK cell activity 12-24 h after administration of low dose natural IFN-cx was also observed by Huddlestone et al., (1979) . In their study, the NK cell activity declined rapidly after 18 h, but remained higher than the pretreatment levels.
In this communication, the effect( (Ortaldo et al., 1977) . The target cell was K562 and the cells were used at effector to target ratios of 40:1, 20:1, 10:1 and 5:1. All assays were performed in triplicate in a total volume of 0.2ml RPMI 1640 containing 10% foetal calf serum (FCS) .
To determine the ability of patient's cells to respond to The studies presented here show that in both chronically (Figure 1 , Table I ) and cyclically ( Figure  2 , Table II), treated patients there was a significant (2-3 fold) augmentation in the NK cell activity on the second day after IFN-a2 therapy. This augmentation was 'short-lived' since the NK cell activity had tapered off when determined on Day 7. In the chronically treated patients, there was a further depression in the NK cell activity during the course of therapy. On the other hand, the NK cell activity in the cyclically treated patients was augmented on the second day after therapy in each of the three cycles. In each cycle, this elevated activity then tapered oft and was identical to its initial level at the beginning of each cycle. Simultaneous assays performed at the same time intervals with in vitro IFN-a2 pretreated lymphocytes showed that the NK cell activity was significantly boostable only on day 0 in the chronically treated patients and on Day 0 of each of the 3 treatment cycles in the cyclically treated patients. This 
NK cell pool. In the cyclically treated patients this pool can be replenished during the 20 days interval between each cycle when no therapy is given. Our current results are in agreement with those reported by Maluish et al. (1983) who also observed that high dose IFN-a2 therapy results in a depression of NK cell activity in 30% of their patients. The most severe depression was observed in patients where a high dose-frequent IFN-a2 administration schedule was used. In contrast, the results presented here show that irrespective of mode of treatment (chronic or cyclic), there was a 'short-lived' augmentation in the NK cell activity after IFN-a2 treatment.
Since NK cells have been implicated to have antitumour effects even against primary tumours (Serrate et al., 1982) , it would be preferable to induce a sustained augmentation of NK cell activity with interferon. In order to achieve this, our current results would argue for a cyclic low dose IFN-a2 administration schedule.
